ECSP11011411A - Derivados de prolina como inhibidores de catepsina - Google Patents
Derivados de prolina como inhibidores de catepsinaInfo
- Publication number
- ECSP11011411A ECSP11011411A EC2011011411A ECSP11011411A ECSP11011411A EC SP11011411 A ECSP11011411 A EC SP11011411A EC 2011011411 A EC2011011411 A EC 2011011411A EC SP11011411 A ECSP11011411 A EC SP11011411A EC SP11011411 A ECSP11011411 A EC SP11011411A
- Authority
- EC
- Ecuador
- Prior art keywords
- catepsin
- inhibitors
- prolin
- derivatives
- prolin derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se refiere a un compuesto de la fórmula (I)en la que A, R1-R6 tienen los significados definidos en la descripción y en las reivindicaciones. El compuesto de la fórmula (I) puede utilizarse como medicamento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09158212 | 2009-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP11011411A true ECSP11011411A (es) | 2011-11-30 |
Family
ID=42261969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2011011411A ECSP11011411A (es) | 2009-04-20 | 2011-08-20 | Derivados de prolina como inhibidores de catepsina |
Country Status (34)
Country | Link |
---|---|
US (1) | US8163793B2 (es) |
EP (1) | EP2421826B1 (es) |
JP (1) | JP5518997B2 (es) |
KR (1) | KR101320790B1 (es) |
CN (1) | CN102405211B (es) |
AR (1) | AR076319A1 (es) |
AU (1) | AU2010241084B2 (es) |
BR (1) | BRPI1013567B8 (es) |
CA (1) | CA2758210C (es) |
CL (1) | CL2011002604A1 (es) |
CO (1) | CO6430459A2 (es) |
CR (1) | CR20110508A (es) |
CY (1) | CY1114764T1 (es) |
DK (1) | DK2421826T3 (es) |
EC (1) | ECSP11011411A (es) |
ES (1) | ES2436550T3 (es) |
HK (1) | HK1166322A1 (es) |
HR (1) | HRP20140030T1 (es) |
IL (1) | IL215065A (es) |
MA (1) | MA33224B1 (es) |
MX (1) | MX2011011094A (es) |
MY (1) | MY153880A (es) |
NZ (1) | NZ595073A (es) |
PE (1) | PE20120911A1 (es) |
PL (1) | PL2421826T3 (es) |
PT (1) | PT2421826E (es) |
RS (1) | RS53122B (es) |
RU (1) | RU2535479C2 (es) |
SG (1) | SG175264A1 (es) |
SI (1) | SI2421826T1 (es) |
TW (1) | TWI418555B (es) |
UA (1) | UA106748C2 (es) |
WO (1) | WO2010121918A1 (es) |
ZA (1) | ZA201107668B (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8524710B2 (en) * | 2010-11-05 | 2013-09-03 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
AU2012334123B2 (en) * | 2011-11-11 | 2016-12-15 | F. Hoffmann-La Roche Ag | Process for the preparation of 1-acyl-4-phenylsulfonylprolinamide derivatives and new intermediates |
KR20140102253A (ko) | 2011-11-25 | 2014-08-21 | 에프. 호프만-라 로슈 아게 | 카텝신의 억제제로서의 피롤리딘 유도체 |
RU2629114C2 (ru) * | 2012-02-07 | 2017-08-24 | Ф. Хоффманн-Ля Рош Аг | Новые производные азетидина |
WO2013120921A1 (en) | 2012-02-17 | 2013-08-22 | F. Hoffmann-La Roche Ag | Novel pyrrolidine derivatives |
CN104379563B (zh) | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
WO2014029722A1 (en) | 2012-08-21 | 2014-02-27 | F. Hoffmann-La Roche Ag | Novel pyridine derivatives |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
USD753137S1 (en) * | 2014-04-06 | 2016-04-05 | Hsien-Wen Chang | Display screen with transitional graphical user interface |
WO2016034602A1 (en) * | 2014-09-05 | 2016-03-10 | F. Hoffmann-La Roche Ag | Solid forms of (2s,4r)-4-[4-(1-methyl-1h-pyrazol-4-yl)-2-trifluoromethyl-benzenesulfonyl]-1-(1-trifluoromethyl-cyclopropanecarbonyl)-pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
EP3194610B1 (en) | 2014-09-18 | 2019-11-13 | F.Hoffmann-La Roche Ag | Anti li p10 antibody |
AR102094A1 (es) | 2014-09-25 | 2017-02-01 | Araxes Pharma Llc | Inhibidores de proteínas kras con una mutación g12c |
US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
CA2981530A1 (en) | 2015-04-10 | 2016-10-13 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
WO2016168540A1 (en) | 2015-04-15 | 2016-10-20 | Araxes Pharma Llc | Fused-tricyclic inhibitors of kras and methods of use thereof |
DK3307262T3 (da) | 2015-06-15 | 2021-08-09 | Nmd Pharma As | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
JP2018533939A (ja) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Rasの阻害剤をスクリーニングするための方法 |
US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
US9938265B2 (en) * | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
EP3419970B1 (en) * | 2016-02-26 | 2020-01-01 | H. Hoffnabb-La Roche Ag | Novel pyrrolidine derivatives |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
CN110248925B (zh) * | 2017-01-24 | 2020-07-17 | 安斯泰来制药株式会社 | 苯基二氟甲基取代脯氨酰胺化合物 |
JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
MX2019013954A (es) | 2017-05-25 | 2020-08-31 | Araxes Pharma Llc | Inhibidores covalentes de kras. |
US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
AR114732A1 (es) * | 2018-09-18 | 2020-10-07 | Hoffmann La Roche | Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco |
CN114105848B (zh) * | 2021-11-24 | 2024-01-12 | 四川同晟生物医药有限公司 | 一种顺式-d-羟脯氨酸衍生物的制备方法 |
WO2023114516A2 (en) * | 2021-12-17 | 2023-06-22 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-permeant inhibitors of viral cysteine proteases |
CN115466225A (zh) * | 2022-08-16 | 2022-12-13 | 中国科学院上海药物研究所 | 一种酰胺类化合物及其制备方法、药物组合物和用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE40911B1 (en) | 1974-04-11 | 1979-09-12 | Schering Ag | Imidazole derivatives and process for their manufacture |
ATE169823T1 (de) | 1991-04-19 | 1998-09-15 | Scios Nova Inc | Bradykinin typische peptide |
AU3359697A (en) * | 1996-07-08 | 1998-02-02 | Yamanouchi Pharmaceutical Co., Ltd. | Bone resorption inhibitors |
SK12882001A3 (sk) * | 1999-03-15 | 2002-04-04 | Axys Pharmaceuticals, Inc. | Zlúčeniny a prípravky ako proteinázové inhibítory |
WO2001047886A1 (en) * | 1999-12-24 | 2001-07-05 | F. Hoffmann-La Roche Ag | Nitrile derivatives as cathepsin k inhibitors |
AU2002254099B2 (en) * | 2001-03-02 | 2006-07-06 | Axys Pharmaceuticals, Inc. | Cathepsin cysteine protease inhibitors |
PT1482924E (pt) * | 2002-03-05 | 2008-08-27 | Axys Pharm Inc | Inibidores de proteases da cisteína catepsina |
JP2006526586A (ja) | 2003-06-02 | 2006-11-24 | エフ.ホフマン−ラ ロシュ アーゲー | ベンズアミドニトリル誘導体 |
US20060252698A1 (en) * | 2005-04-20 | 2006-11-09 | Malcolm Bruce A | Compounds for inhibiting cathepsin activity |
AU2007253819B2 (en) * | 2006-05-23 | 2011-02-17 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
-
2010
- 2010-04-13 WO PCT/EP2010/054792 patent/WO2010121918A1/en active Application Filing
- 2010-04-13 PL PL10713457T patent/PL2421826T3/pl unknown
- 2010-04-13 PT PT107134579T patent/PT2421826E/pt unknown
- 2010-04-13 UA UAA201113185A patent/UA106748C2/uk unknown
- 2010-04-13 CA CA2758210A patent/CA2758210C/en active Active
- 2010-04-13 AU AU2010241084A patent/AU2010241084B2/en active Active
- 2010-04-13 EP EP10713457.9A patent/EP2421826B1/en active Active
- 2010-04-13 NZ NZ595073A patent/NZ595073A/xx unknown
- 2010-04-13 RU RU2011146872/04A patent/RU2535479C2/ru active
- 2010-04-13 SG SG2011076114A patent/SG175264A1/en unknown
- 2010-04-13 DK DK10713457.9T patent/DK2421826T3/da active
- 2010-04-13 KR KR1020117027505A patent/KR101320790B1/ko active IP Right Grant
- 2010-04-13 BR BRPI1013567A patent/BRPI1013567B8/pt active IP Right Grant
- 2010-04-13 MY MYPI2011004998A patent/MY153880A/en unknown
- 2010-04-13 MX MX2011011094A patent/MX2011011094A/es active IP Right Grant
- 2010-04-13 CN CN201080017460.5A patent/CN102405211B/zh active Active
- 2010-04-13 JP JP2012506439A patent/JP5518997B2/ja active Active
- 2010-04-13 RS RS20130589A patent/RS53122B/en unknown
- 2010-04-13 SI SI201030488T patent/SI2421826T1/sl unknown
- 2010-04-13 MA MA34287A patent/MA33224B1/fr unknown
- 2010-04-13 ES ES10713457.9T patent/ES2436550T3/es active Active
- 2010-04-13 PE PE2011001834A patent/PE20120911A1/es active IP Right Grant
- 2010-04-16 US US12/761,427 patent/US8163793B2/en active Active
- 2010-04-16 AR ARP100101275A patent/AR076319A1/es active IP Right Grant
- 2010-04-19 TW TW099112228A patent/TWI418555B/zh active
-
2011
- 2011-08-20 EC EC2011011411A patent/ECSP11011411A/es unknown
- 2011-09-08 IL IL215065A patent/IL215065A/en active IP Right Grant
- 2011-09-09 CO CO11116894A patent/CO6430459A2/es not_active Application Discontinuation
- 2011-09-28 CR CR20110508A patent/CR20110508A/es unknown
- 2011-10-19 CL CL2011002604A patent/CL2011002604A1/es unknown
- 2011-10-19 ZA ZA2011/07668A patent/ZA201107668B/en unknown
-
2012
- 2012-07-18 HK HK12107038.5A patent/HK1166322A1/xx unknown
-
2014
- 2014-01-10 HR HRP20140030AT patent/HRP20140030T1/hr unknown
- 2014-01-17 CY CY20141100041T patent/CY1114764T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6430459A2 (es) | Derivados de prolina como inhibidores de catepsina | |
ECSP13013074A (es) | Nuevos derivados de piridina | |
CR20150250A (es) | Nuevos derivados de piridina | |
CR20150277A (es) | Piridina-2-amidas utiles como agonistas cb2 | |
CR20150204A (es) | Nuevos derivados de piridina | |
CR20150447A (es) | Nuevos derivados de pirazol | |
CO6741154A2 (es) | Compuestos de triazolopiridina | |
ECSP12012174A (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
CR20150210A (es) | Nuevos derivados de pirazina como agonistas receptores de cb2 | |
MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
ECSP13012499A (es) | Nuevos compuestos | |
CO6620065A2 (es) | Compuestos heteroarilo nitrogenados | |
CR20150045A (es) | Inhibidores de hepatitis c | |
UA108101C2 (xx) | Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів | |
CO6362015A2 (es) | Derivados de acido 1-amino-2ciclobutiletilboronico | |
SV2011003853A (es) | Compuestos organicos | |
CR20150440A (es) | Nuevos derivados de piridina | |
CY1122115T1 (el) | Παραγωγα ν1-ακυλο-5-φθοροπυριμιδινονης | |
CR20110680A (es) | Sulfonamidas heterociclicas, usos y composiciones farmacéuticas de las mismas | |
DOP2009000169A (es) | Derivados ciclados como inhibidores de eg-5 | |
CR20150511A (es) | Nuevos derivados de purina | |
CR20110269A (es) | Lactamas como inhibidores de beta secretasa | |
MA33948B1 (fr) | Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques. | |
CR20150555A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina | |
CR20180298A (es) | Nuevos derivados de fenilo |